CoChat

A phase 2 trial of dasatinib in advanced melanoma

Open access
Kluger, Harriet M., Dudek, Arkadiuz Z., McCann, Carrie, Ritacco, Jean, Southard, Nadine, Jilaveanu, Lucia B., Molinaro, Annette, Sznol, Mario · 2011 · Cancer
Cited by 151

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Inhibiting src kinases (non‐receptor tyrosine kinase signaling intermediates) reduces melanoma cell proliferation and invasion. Dasatinib inhibits c‐kit, PDGFβR, and EPHA2 and src kinases c‐src, c‐Yes, Lck, and Fyn. A phase 2 trial of dasatinib in melanoma was conducted to assess response rate (RR), progression‐free survival (PFS), and toxicity. METHODS: Adults with stage 3/4 chemotherapy‐naïve unresectable melanoma were eligible. Dasatinib was initially administered at 100 mg twice daily continuously to 17 patients. Due to toxicity, the starting dosage was decreased to 70 mg twice daily. Tumor assessments occurred every 8 weeks. RESULTS: Thirty‐nine patients were enrolled, 36 of whom were evaluable for activity and toxicity. Five, 4, and 3 patients had acral‐lentiginous, ocular, or mucosal primaries, respectively. Two patients had confirmed partial responses lasting 64 and 24 weeks (RR 5%). Three patients had minor responses lasting 136, 64, and 28 weeks, and 1 patient who was responding discontinued due to noncompliance. The median PFS was 8 weeks; the 6‐month PFS rate was 13%. One patient with an exon‐13 c‐kit mutation had a partial response, whereas disease in another patient with an exon‐11 c‐kit mutation progressed. Common toxicities were fatigue, dyspnea, and pleural effusion. CONCLUSIONS: Daily dasatinib has minimal activity in unselected melanoma patients, excluding those with c‐kit mutations. The study did not meet the prespecified endpoints of 30% response rate or 6‐month PFS. Dasatinib was poorly tolerated overall, often requiring dose reduction or interruption. Because activity was observed in a small subset without c‐kit mutations, identifying predictive biomarkers is important for future development of dasatinib in melanoma alone or in combination trials. Cancer 2011. © 2010 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.25766

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 151

Metadata

Authors
Kluger, H. M., Dudek, A. Z., McCann, C., Ritacco, J., Southard, N., Jilaveanu, L. B., Molinaro, A., & Sznol, M.
Venue
Cancer
Publisher
Wiley
Published
2010-11-29
Volume
117
Issue
10
Pages
2202-2208
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W2063346434
Cited by
151
References
6
FWCI
6.26
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A phase 2 trial of dasatinib in advanced melanoma. https://app.cochat.ai/papers/10.1002/cncr.25766
The paper
Kluger, H. M., Dudek, A. Z., McCann, C., Ritacco, J., Southard, N., Jilaveanu, L. B., Molinaro, A., & Sznol, M. (2011). A phase 2 trial of dasatinib in advanced melanoma. Cancer. https://doi.org/10.1002/cncr.25766

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.